CymaBay Therapeutics, Inc.
CBAY
주식 순위
#5830
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
주가
$32.48
마지막 동기화: 2024-03-25
시가총액
$2.24B
변동 (1일)
0.00%
변동 (1년)
-0.01%
국가
US
거래 CymaBay Therapeutics, Inc. (CBAY)
카테고리
Healthcare
의 시가총액 CymaBay Therapeutics, Inc.(CBAY)
시가총액: $2.24B
October 2026 기준으로 CymaBay Therapeutics, Inc.의 시가총액은 $2.24B입니다. 이는 당사 데이터에 따르면 CymaBay Therapeutics, Inc.이 세계에서 5830th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2018부터 2026까지 CymaBay Therapeutics, Inc.의 시가총액 기록
